Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China

Carcinogenesis

Volumn 32, Issue 6, 2011, Pages 860-865

  Muñozy, Alvaro ^a   Chen, Jian Guo ^b   Egner, Patricia A ^a   Marshall, Melinda L ^a   Johnson, Jamie L ^a   Schneider, Michael F ^a   Lu, Jian Hua ^b   Zhu, Yuan Rong ^b   Wang, Jin Bing ^b   Chen, Tao Yang ^b   Kensler, Thomas W ^a   Groopman, John D ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b QIDONG LIVER CANCER INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CANCER RISK; CHINA; CONTROLLED STUDY; GENE MUTATION; GENETIC RISK; HEPATITIS B; HETEROZYGOTE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

EID: 79958200857     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr055     Document Type: Article

References (50)

1. Wang,X.W. et al. (2002) Molecular pathogenesis of human hepatocellular carcinoma. Toxicology, 181-182, 43-47.
2. Ferlay,J. et al. (2010) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide, IARC CancerBase No. 10 [Internet]. Lyon, International Agency for Research on Cancer. http://globocan.iarc.fr.
3. Kensler,T.W. et al. (2003) Translational strategies for cancer prevention in liver. Nat. Rev., 3, 321-329.
4. Block,T.M. et al. (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene, 22, 5093-5107.
5. Kensler,T.W. et al. (2004) Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology, 127, S310-S318.
6. Kew,M.C. (2002) Epidemiology of hepatocellular carcinoma. Toxicology, 181-182, 35-38.
7. Lee,W.M. (1997) Hepatitis B virus infection. N. Engl. J. Med., 337, 1733-1745.
8. Ming,L. et al. (2002) Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology, 36, 1214-1220.
9. Kirk,G.D. et al. (2006) Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis, 27, 2070-2082.
10. Neuveut,C. et al. (2010) Mechanisms of HBV-related hepatocarcinogenesis. J. Hepatol., 52, 594-604.
11. Tong,S. et al. (2005) Hepatitis B virus e antigen variants. Int. J. Med. Sci., 2, 2-7.
12. Tong,S. (2005) Mechanism of HBV genome variability and replication of HBV mutants. J. Clin. Virol., 34 (suppl. 1), S134-S138.
13. Kuang,S.Y. et al. (2004) Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci USA, 101, 3575-3580.
14. Baptista,M. et al. (1999) High prevalence of 1762 T 1764 A mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology, 29, 946-953.
15. Yuan,J.-M. et al. (2009) Prospective evaluation of hepatitis B 1762T/1764A mutations on hepatocellular carcinoma development in Shanghai, China. Cancer Epidemiol. Biomarkers Prev., 18, 590-594.
16. Liu,S. et al. (2009) Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J. Natl Cancer Inst., 101, 1066-1082.
17. Hsia,C.C. et al. (1996) Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet, 348, 625-626.
18. Hou,J. et al. (1999) T1762/A1764 variants of the basal core promoter of hepatitis B virus: serological and clinical correlations in Chinese patients. Liver, 19, 411-417.
19. Sidransky,D. (2002) Emerging molecular markers of cancer. Nature, 2, 210-219.
20. Jackson,P.E. et al. (2001) Specific p.53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res., 61, 33-35.
21. Jen,J. et al. (2000) An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann. N. Y. Acad. Sci., 906, 8-12.
22. Anker,P. et al. (1999) Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev., 18, 65-73.
23. Chen,J.G. et al. (2007) Acceleration to death from liver cancer in people with hepatitis B viral mutations detected in plasma by mass spectrometry. Cancer Epidemiol. Biomarkers Prev., 16, 1213-1218.
24. Chen,J.G. et al. (2003) Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J. Med. Screen., 10, 204-209.
25. Esty,W. et al. (2003) The box-percentile Plot. J. Stat. Softw., 8, 1-14.
26. Okamoto,H. et al. (1994) Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J. Virol., 68, 8102-8110.
27. Hadziyannis,S.J. et al. (2001) Hepatitis B e antigen-negative chronic hepatitis B. Hepatology, 34, 617-624.
28. Yotsuyanagi,H. et al. (2002) Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J. Hepatol., 37, 355-363.
29. Parekh,S. et al. (2003) Genome replication, virion secretion and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J. Virol., 77, 6601-6612.
30. Tang,H. et al. (2006) Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci., 97, 977-983.
31. Zheng,Y. et al. (2004) Regulation of hepatitis B virus core promoter by transcription factors HNF1 and HNF4 and the viral X protein. J. Virol., 78, 6908-6914.
32. Su,S.C. et al. (2010) Spatial analyses identify the geographic source of patients at a National Cancer Institute Comprehensive Cancer Center The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clin. Cancer Res., 16, 1065-1072.
33. Yuen,M.F. et al. (2003) Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology, 37, 562-567.
34. Lindh,M. et al. (1999) Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J. Infect. Dis., 179, 775-782.
35. Cho,S.W. et al. (1999) Analysis of the precore and core promoter DNA sequence in liver tissues from patients with hepatocellular carcinoma. J. Korean Med. Sci., 14, 424-430.
36. Yin,J. et al. (2010) Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a communitybased study. Cancer Epidemiol. Biomarkers Prev., 19, 777-786.
37. Cooke,M.S. et al. (2003) Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J., 17, 1195-1214.
38. Suspene,R. et al. (2005) Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl Acad. Sci. USA, 102, 8321-8326.
39. Noguchi,C. et al. (2005) G to A hypermutation of hepatitis B virus. Hepatology, 41, 626-633.
40. Brechot,C. et al. (2010) Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms. Pathol. Biol. (Paris), 58, 278-287.
41. McMahon,B.J. (2010) Natural history of chronic hepatitis B. Clin. Liver Dis., 14, 381-396.
42. Tsai,W.L. et al. (2010) Viral hepatocarcinogenesis. Oncogene, 29, 2309-2324.
43. Yang,H.-I. et al. (2008) Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl Cancer Inst., 100, 1134-1143.
44. Su,S.C. et al. (2010) Spatial analyses identify the geographic source of patients at a National Cancer Institute Comprehensive Cancer Center. Clin. Cancer Res., 16, 1065-1072.
45. Qian,G.S. et al. (1994) A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev., 3, 3-10.
46. Liu,S. et al. (2011) A matched case-control study of hepatitis B virus mutations in the preS and core promoter regions associated independently with hepatocellular carcinoma. J. Med. Virol., 83, 45-53.
47. Qu,L.S. et al. (2010) Combined pre-S deletion and core promoter mutations related to hepatocellular carcinoma: a nested case-control study in China Liver Cancer Epidemic in China: Past; Present and Future Comparison study on the complete sequence of hepatitis B virus identifies new mutations in core gene associated with hepatocellular carcinoma [The association of hepatitis B virus genotype and the basal core promoter mutation in Qidong, China]. Hepatol. Res., 25, 6.
48. Cornblatt,B.S. et al. (2007) Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis, 28, 1485-1490.
49. Yuen,M.F. et al. (2008) Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut, 57, 98-102.
50. Zhu,Y. et al. (2010) Comparison study on the complete sequence of hepatitis B virus identifies new mutations in core gene associated with hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev., 19, 2623-2630.